BIOSYENT INC (RX.CA) Stock Fundamental Analysis

TSX-V:RX • CA0906901081

15.8 CAD
0 (0%)
Last: Feb 25, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

8

RX gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 33 industry peers in the Pharmaceuticals industry. Both the health and profitability get an excellent rating, making RX a very profitable company, without any liquidiy or solvency issues. RX is not priced too expensively while it is growing strongly. Keep and eye on this one! This makes RX very considerable for growth and quality investing!


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

  • RX had positive earnings in the past year.
  • In the past year RX had a positive cash flow from operations.
  • RX had positive earnings in each of the past 5 years.
  • RX had a positive operating cash flow in each of the past 5 years.
RX.CA Yearly Net Income VS EBIT VS OCF VS FCFRX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

1.2 Ratios

  • With an excellent Return On Assets value of 18.07%, RX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 21.64%, RX belongs to the top of the industry, outperforming 93.94% of the companies in the same industry.
  • The Return On Invested Capital of RX (20.81%) is better than 96.97% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for RX is significantly above the industry average of 8.54%.
  • The last Return On Invested Capital (20.81%) for RX is above the 3 year average (16.58%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 18.07%
ROE 21.64%
ROIC 20.81%
ROA(3y)15.54%
ROA(5y)14.96%
ROE(3y)18.57%
ROE(5y)17.96%
ROIC(3y)16.58%
ROIC(5y)16.4%
RX.CA Yearly ROA, ROE, ROICRX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20 25

1.3 Margins

  • Looking at the Profit Margin, with a value of 20.47%, RX belongs to the top of the industry, outperforming 87.88% of the companies in the same industry.
  • In the last couple of years the Profit Margin of RX has remained more or less at the same level.
  • With an excellent Operating Margin value of 26.75%, RX belongs to the best of the industry, outperforming 90.91% of the companies in the same industry.
  • RX's Operating Margin has declined in the last couple of years.
  • With an excellent Gross Margin value of 77.46%, RX belongs to the best of the industry, outperforming 96.97% of the companies in the same industry.
  • In the last couple of years the Gross Margin of RX has remained more or less at the same level.
Industry RankSector Rank
OM 26.75%
PM (TTM) 20.47%
GM 77.46%
OM growth 3Y-3.53%
OM growth 5Y-2.73%
PM growth 3Y-1.85%
PM growth 5Y0.35%
GM growth 3Y0.17%
GM growth 5Y0.46%
RX.CA Yearly Profit, Operating, Gross MarginsRX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

10

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), RX is creating value.
  • The number of shares outstanding for RX has been reduced compared to 1 year ago.
  • RX has less shares outstanding than it did 5 years ago.
  • The debt/assets ratio for RX has been reduced compared to a year ago.
RX.CA Yearly Shares OutstandingRX.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M
RX.CA Yearly Total Debt VS Total AssetsRX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • RX has an Altman-Z score of 17.15. This indicates that RX is financially healthy and has little risk of bankruptcy at the moment.
  • With an excellent Altman-Z score value of 17.15, RX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • The Debt to FCF ratio of RX is 0.11, which is an excellent value as it means it would take RX, only 0.11 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of RX (0.11) is better than 100.00% of its industry peers.
  • A Debt/Equity ratio of 0.02 indicates that RX is not too dependend on debt financing.
  • RX's Debt to Equity ratio of 0.02 is fine compared to the rest of the industry. RX outperforms 78.79% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 0.11
Altman-Z 17.15
ROIC/WACC2.42
WACC8.6%
RX.CA Yearly LT Debt VS Equity VS FCFRX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.3 Liquidity

  • A Current Ratio of 5.06 indicates that RX has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 5.06, RX belongs to the top of the industry, outperforming 93.94% of the companies in the same industry.
  • RX has a Quick Ratio of 4.23. This indicates that RX is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of RX (4.23) is better than 93.94% of its industry peers.
Industry RankSector Rank
Current Ratio 5.06
Quick Ratio 4.23
RX.CA Yearly Current Assets VS Current LiabilitesRX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 24.84% over the past year.
  • Measured over the past years, RX shows a quite strong growth in Earnings Per Share. The EPS has been growing by 15.02% on average per year.
  • The Revenue has grown by 22.22% in the past year. This is a very strong growth!
  • RX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.33% yearly.
EPS 1Y (TTM)24.84%
EPS 3Y8.39%
EPS 5Y15.02%
EPS Q2Q%19.41%
Revenue 1Y (TTM)22.22%
Revenue growth 3Y6.97%
Revenue growth 5Y10.33%
Sales Q2Q%27.9%

3.2 Future

  • Based on estimates for the next years, RX will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.80% on average per year.
  • RX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.07% yearly.
EPS Next Y20.96%
EPS Next 2Y19.25%
EPS Next 3Y15.8%
EPS Next 5YN/A
Revenue Next Year23.16%
Revenue Next 2Y12.62%
Revenue Next 3Y11.07%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
RX.CA Yearly Revenue VS EstimatesRX.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M 40M
RX.CA Yearly EPS VS EstimatesRX.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.2 0.4 0.6 0.8

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 25.48, the valuation of RX can be described as expensive.
  • Based on the Price/Earnings ratio, RX is valued a bit cheaper than the industry average as 72.73% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 27.05. RX is around the same levels.
  • Based on the Price/Forward Earnings ratio of 17.80, the valuation of RX can be described as rather expensive.
  • Based on the Price/Forward Earnings ratio, RX is valued a bit cheaper than 72.73% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 28.03. RX is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 25.48
Fwd PE 17.8
RX.CA Price Earnings VS Forward Price EarningsRX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, RX is valued a bit cheaper than the industry average as 60.61% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, RX is valued a bit cheaper than the industry average as 72.73% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 22.45
EV/EBITDA 12.31
RX.CA Per share dataRX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The excellent profitability rating of RX may justify a higher PE ratio.
  • RX's earnings are expected to grow with 15.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.22
PEG (5Y)1.7
EPS Next 2Y19.25%
EPS Next 3Y15.8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. Dividend

5.1 Amount

  • RX has a Yearly Dividend Yield of 1.40%.
  • Compared to an average industry Dividend Yield of 0.25, RX pays a better dividend. On top of this RX pays more dividend than 93.94% of the companies listed in the same industry.
  • RX's Dividend Yield is slightly below the S&P500 average, which is at 1.80.
Industry RankSector Rank
Dividend Yield 1.4%

5.2 History

  • RX has been paying a dividend for over 5 years, so it has already some track record.
  • The dividend of RX decreased in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years2
Div Non Decr Years2
RX.CA Yearly Dividends per shareRX.CA Yearly Dividends per shareYearly Dividends per share 2022 2023 2024 2025 2026 0.05 0.1 0.15

5.3 Sustainability

  • 25.51% of the earnings are spent on dividend by RX. This is a low number and sustainable payout ratio.
DP25.51%
EPS Next 2Y19.25%
EPS Next 3Y15.8%
RX.CA Yearly Income VS Free CF VS DividendRX.CA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
RX.CA Dividend Payout.RX.CA Dividend Payout, showing the Payout Ratio.RX.CA Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

BIOSYENT INC

TSX-V:RX (2/25/2026, 7:00:00 PM)

15.8

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-20
Earnings (Next)03-11
Inst Owners3.68%
Inst Owner ChangeN/A
Ins Owners17.83%
Ins Owner ChangeN/A
Market Cap181.38M
Revenue(TTM)42.18M
Net Income(TTM)8.63M
Analysts82.86
Price Target13.77 (-12.85%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.4%
Yearly Dividend0.18
Dividend Growth(5Y)N/A
DP25.51%
Div Incr Years2
Div Non Decr Years2
Ex-Date02-27
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)3.85%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.81%
Valuation
Industry RankSector Rank
PE 25.48
Fwd PE 17.8
P/S 4.3
P/FCF 22.45
P/OCF 22.28
P/B 4.55
P/tB 5.19
EV/EBITDA 12.31
EPS(TTM)0.62
EY3.92%
EPS(NY)0.89
Fwd EY5.62%
FCF(TTM)0.7
FCFY4.45%
OCF(TTM)0.71
OCFY4.49%
SpS3.67
BVpS3.48
TBVpS3.04
PEG (NY)1.22
PEG (5Y)1.7
Graham Number6.96
Profitability
Industry RankSector Rank
ROA 18.07%
ROE 21.64%
ROCE 27.74%
ROIC 20.81%
ROICexc 48.97%
ROICexgc 68.62%
OM 26.75%
PM (TTM) 20.47%
GM 77.46%
FCFM 19.16%
ROA(3y)15.54%
ROA(5y)14.96%
ROE(3y)18.57%
ROE(5y)17.96%
ROIC(3y)16.58%
ROIC(5y)16.4%
ROICexc(3y)59.42%
ROICexc(5y)88.26%
ROICexgc(3y)72.91%
ROICexgc(5y)116.75%
ROCE(3y)22.1%
ROCE(5y)21.86%
ROICexgc growth 3Y-33.84%
ROICexgc growth 5Y-15.21%
ROICexc growth 3Y-35.8%
ROICexc growth 5Y-16.72%
OM growth 3Y-3.53%
OM growth 5Y-2.73%
PM growth 3Y-1.85%
PM growth 5Y0.35%
GM growth 3Y0.17%
GM growth 5Y0.46%
F-Score7
Asset Turnover0.88
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 0.11
Debt/EBITDA 0.06
Cap/Depr 6.81%
Cap/Sales 0.14%
Interest Coverage 217.41
Cash Conversion 67.01%
Profit Quality 93.59%
Current Ratio 5.06
Quick Ratio 4.23
Altman-Z 17.15
F-Score7
WACC8.6%
ROIC/WACC2.42
Cap/Depr(3y)10.2%
Cap/Depr(5y)10.36%
Cap/Sales(3y)0.16%
Cap/Sales(5y)0.17%
Profit Quality(3y)95.24%
Profit Quality(5y)108.02%
High Growth Momentum
Growth
EPS 1Y (TTM)24.84%
EPS 3Y8.39%
EPS 5Y15.02%
EPS Q2Q%19.41%
EPS Next Y20.96%
EPS Next 2Y19.25%
EPS Next 3Y15.8%
EPS Next 5YN/A
Revenue 1Y (TTM)22.22%
Revenue growth 3Y6.97%
Revenue growth 5Y10.33%
Sales Q2Q%27.9%
Revenue Next Year23.16%
Revenue Next 2Y12.62%
Revenue Next 3Y11.07%
Revenue Next 5YN/A
EBIT growth 1Y37.32%
EBIT growth 3Y3.2%
EBIT growth 5Y7.32%
EBIT Next Year39.54%
EBIT Next 3Y16.91%
EBIT Next 5YN/A
FCF growth 1Y22.97%
FCF growth 3Y23.38%
FCF growth 5Y17.21%
OCF growth 1Y24.46%
OCF growth 3Y22.83%
OCF growth 5Y14.5%

BIOSYENT INC / RX.CA FAQ

What is the fundamental rating for RX stock?

ChartMill assigns a fundamental rating of 8 / 10 to RX.CA.


What is the valuation status for RX stock?

ChartMill assigns a valuation rating of 5 / 10 to BIOSYENT INC (RX.CA). This can be considered as Fairly Valued.


What is the profitability of RX stock?

BIOSYENT INC (RX.CA) has a profitability rating of 9 / 10.


What is the valuation of BIOSYENT INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for BIOSYENT INC (RX.CA) is 25.48 and the Price/Book (PB) ratio is 4.55.


Can you provide the dividend sustainability for RX stock?

The dividend rating of BIOSYENT INC (RX.CA) is 4 / 10 and the dividend payout ratio is 25.51%.